{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:42:57Z","timestamp":1788918177055,"version":"build-2803163510"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ejim.2020.04.050","type":"journal-article","created":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T20:20:16Z","timestamp":1589142016000},"page":"9-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Therapeutic strategies for virus-negative myocarditis: a comprehensive review"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-7714","authenticated-orcid":false,"given":"Giacomo","family":"De Luca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Campochiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sartorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Peretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-315X","authenticated-orcid":false,"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejim.2020.04.050_bib0001","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.CIR.93.5.841","article-title":"Report of the 1995 World Health Organization\/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies","volume":"93","author":"Richardson","year":"1996","journal-title":"Circulation"},{"issue":"9716","key":"10.1016\/j.ejim.2020.04.050_bib0002","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(09)62023-7","article-title":"Dilated cardiomyopathy","volume":"375","author":"Jefferies","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.050_bib0003","first-page":"3","article-title":"Myocarditis. A histopathologic definition and classification","volume":"1","author":"Aretz","year":"1987","journal-title":"Am J Cardiovasc Pathol"},{"issue":"6","key":"10.1016\/j.ejim.2020.04.050_bib0004","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1161\/CIRCULATIONAHA.105.584532","article-title":"Myocarditis: current trends in diagnosis and treatment","volume":"113","author":"Magnani","year":"2006","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ejim.2020.04.050_bib0005","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s10741-012-9364-5","article-title":"Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management","volume":"18","author":"Caforio","year":"2013","journal-title":"Heart Fail Rev"},{"issue":"6","key":"10.1016\/j.ejim.2020.04.050_bib0006","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s10875-009-9339-z","article-title":"Myocarditis: infection versus autoimmunity","volume":"29","author":"Rose","year":"2009","journal-title":"J Clin Immunol"},{"issue":"8","key":"10.1016\/j.ejim.2020.04.050_bib0007","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.autrev.2017.05.021","article-title":"Myocarditis in auto-immune or auto-inflammatory diseases","volume":"16","author":"Comarmond","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.050_bib0008","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/03009742.2016.1157626","article-title":"Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst","volume":"46","author":"De Luca","year":"2017","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.ejim.2020.04.050_bib0009","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/03009742.2018.1493744","article-title":"Unexpected acute lymphocytic virus-negative myocarditis in a patient with limited cutaneous systemic sclerosis: a case report","volume":"48","author":"De Luca","year":"2019","journal-title":"Scand J Rheumatol"},{"issue":"20","key":"10.1016\/j.ejim.2020.04.050_bib0010","first-page":"1977","article-title":"Troponin in stable ischemic heart disease and diabetes","volume":"373","author":"Bosello","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejim.2020.04.050_bib0011","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.semarthrit.2013.07.006","article-title":"Recognizing and treating myocarditis in recent- onset systemic sclerosis heart disease: Potential utility of immunosuppressive therapy in cardiac damage progression","volume":"43","author":"Pieroni","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ejim.2020.04.050_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153012","article-title":"Prognostic role of ventricular ectopic beats in systemic sclerosis: a prospective cohort study shows ECG indexes predicting the worse outcome","volume":"11","author":"De Luca","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2020.04.050_bib0013","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejim.2018.10.013","article-title":"Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: a prospective study","volume":"60","author":"Bosello","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.04.050_bib0014","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijcard.2017.03.088","article-title":"QTc interval prolongation in Systemic Sclerosis: correlations with clinical variables and arrhythmic risk","volume":"239","author":"De Luca","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2020.04.050_bib0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2018.11.104","article-title":"Impact of systemic immune-mediated diseases on clinical features and prognosis of patients with biopsy-proved myocarditis","volume":"280","author":"Peretto","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2020.04.050_bib0016","first-page":"1","article-title":"Successful use of sirolimus in a patient with cardiac microangiopathy in primary antiphospholipid syndrome","author":"Sartorelli","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ejim.2020.04.050_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102330","article-title":"Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: a prospective cohort study","volume":"106","author":"De Luca","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ejim.2020.04.050_bib0018","article-title":"Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis","author":"Campochiaro","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2020.04.050_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez658","article-title":"Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis","author":"De Luca","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"10.1016\/j.ejim.2020.04.050_bib0020","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.ejim.2020.04.050_bib0021","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1161\/CIRCULATIONAHA.117.033305","article-title":"Letter by Campochiaro et\u00a0al regarding article, \"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"137","author":"Campochiaro","year":"2018","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.ejim.2020.04.050_bib0022","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMc0911362","article-title":"Human parvovirus B19-associated myocarditis","volume":"362","author":"Bock","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2020.04.050_bib0023","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jtbi.2014.11.022","article-title":"Unresolved issues in theories of autoimmune disease using myocarditis as a framework","volume":"375","author":"Root-Bernstein","year":"2015","journal-title":"J Theor Biol"},{"issue":"33","key":"10.1016\/j.ejim.2020.04.050_bib0024","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ejim.2020.04.050_bib0025","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nrcardio.2015.108","article-title":"Viral myocarditis \u2013 diagnosis, treatment options, and current controversies","volume":"12","author":"Pollack","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2020.04.050_bib0026","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/hrt.2004.045518","article-title":"Sudden adult death syndrome and other nonischaemic causes of sudden cardiac death","volume":"92","author":"Fabre","year":"2006","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.ejim.2020.04.050_bib0027","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.hrthm.2018.11.024","article-title":"Arrhythmias in myocarditis: state of the art","volume":"16","author":"Peretto","year":"2019","journal-title":"Heart Rhythm"},{"issue":"9","key":"10.1016\/j.ejim.2020.04.050_bib0028","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jacc.2020.01.036","article-title":"Ventricular arrhythmias in myocarditis: characterization and relationships with myocardial inflammation","volume":"75","author":"Peretto","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ejim.2020.04.050_bib0029","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1056\/NEJM199508033330501","article-title":"A clinical trial of immunosuppressive therapy for myocarditis. The myocarditis treatment trial investigators","volume":"333","author":"Mason","year":"1995","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.ejim.2020.04.050_bib0030","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1378\/chest.114.5.1484","article-title":"Necrotizing myocardial vasculitis in Churg-Strauss syndrome: clinicohistologic evaluation of steroids and immunosuppressive therapy","volume":"114","author":"Frustaci","year":"1998","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ejim.2020.04.050_bib0031","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.amjcard.2018.10.021","article-title":"Cardiac sarcoidosis","volume":"123","author":"Tan","year":"2019","journal-title":"Am J Cardiol"},{"issue":"26","key":"10.1016\/j.ejim.2020.04.050_bib0032","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJM199706263362603","article-title":"Idiopathic giant-cell myocarditis: natural history and treatment: multicenter giant cell myocardi- tis study group investigators","volume":"336","author":"Cooper","year":"1997","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejim.2020.04.050_bib0033","first-page":"1601","volume":"17","author":"Priori","year":"2015","journal-title":"Europace"},{"issue":"8","key":"10.1016\/j.ejim.2020.04.050_bib0034","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"10.1016\/j.ejim.2020.04.050_bib0035","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/eurheartj\/ehp249","article-title":"Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study","volume":"30","author":"Frustaci","year":"2009","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ejim.2020.04.050_bib0036","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/01.CIR.0000048147.15962.31","article-title":"Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders","volume":"107","author":"Frustaci","year":"2003","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ejim.2020.04.050_bib0037","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.amjcard.2008.07.041","article-title":"Giant cell myocarditis treatment trial investigators. Usefulness of immunosuppression for giant cell myocarditis","volume":"102","author":"Cooper","year":"2008","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.ejim.2020.04.050_bib0038","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00392-016-1011-z","article-title":"Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy","volume":"105","author":"Escher","year":"2016","journal-title":"Clin Res Cardiol"},{"issue":"26","key":"10.1016\/j.ejim.2020.04.050_bib0039","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1097\/MD.0000000000000798","article-title":"Myocarditis in patients with antisynthetase syndrome: prevalence, presentation, and outcomes","volume":"94","author":"Dieval","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.ejim.2020.04.050_bib0040","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s10067-017-3971-4","article-title":"Lupus myocarditis receiving the rituximab therapy\u2014a monocentric retrospective study","volume":"37","author":"Wang","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.ejim.2020.04.050_bib0041","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1177\/0961203318770018","article-title":"Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies","volume":"27","author":"Tanwani","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.ejim.2020.04.050_bib0042","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/389720","article-title":"Effects of methotrexate on plasma cytokines and cardiac remodeling and function in postmyocarditis rats","volume":"2009","author":"Zhang","year":"2009","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.ejim.2020.04.050_bib0043","first-page":"168","article-title":"Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis","volume":"65","author":"Tian","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1016\/j.ejim.2020.04.050_bib0044","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.yjmcc.2015.07.010","article-title":"Pharmacological activation of AMPK prevents Drp1-mediated mitochondrial fission and alleviates endoplasmic reticulum stress-associated endothelial dysfunction","volume":"86","author":"Li","year":"2015","journal-title":"J Mol Cell Cardiol"},{"issue":"17","key":"10.1016\/j.ejim.2020.04.050_bib0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/MD.0000000000000112","article-title":"Myocarditis in adult-onset still disease","volume":"93","author":"Gerfaud-Valentin","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejim.2020.04.050_bib0046","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijcard.2018.11.131","article-title":"Treatment of cardiac sarcoidosis: a comparative study of steroids and steroids plus immunosuppressive drugs","volume":"276","author":"Ballul","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2020.04.050_bib0047","doi-asserted-by":"crossref","DOI":"10.1097\/RHU.0000000000000897","article-title":"Efficacy and safety of methotrexate for the treatment of autoimmune virus-negative myocarditis: a case series","author":"Campochiaro","year":"2018","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.050_bib0048","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3899\/jrheum.160493","article-title":"Lupus myocarditis: initial presentation and longterm outcomes in a multicentric series of 29 patients","volume":"44","author":"Thomas","year":"2017","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.ejim.2020.04.050_bib0049","article-title":"Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course: a case series","volume":"3","author":"Tsch\u00f6pe","year":"2019","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.ejim.2020.04.050_bib0050","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-319-57613-8_10","article-title":"Cardiac autoimmunity: myocarditis","volume":"1003","author":"Bracamonte-Baran","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1016\/j.ejim.2020.04.050_bib0051","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1536\/ihj.18-299","article-title":"Intravenous immunoglobulin therapy for acute myocarditis in children and adults","volume":"60","author":"Huang","year":"2019","journal-title":"Int Heart J"},{"issue":"3","key":"10.1016\/j.ejim.2020.04.050_bib0052","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.revmed.2016.05.005","article-title":"Off-label use of intravenous immunoglobulin therapy in the treatment of lupus myocarditis: Two case reports and literature review","volume":"38","author":"Charhon","year":"2017","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.ejim.2020.04.050_bib0053","doi-asserted-by":"crossref","unstructured":"Cacciatore C, Riviere S, Cohen A, Gatfosse M, Ederhy S, Fain O, et\u00a0al. Systemic sclerosis: Efficacy of intravenous immunoglobulins in severe cardiac involvement?. Rev Med Interne. 2018 Jul;39(7):594-6. 10.1016\/j.revmed.2017.12.013.","DOI":"10.1016\/j.revmed.2017.12.013"},{"issue":"6","key":"10.1016\/j.ejim.2020.04.050_bib0054","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.autrev.2008.04.001","article-title":"Intravenous immunoglobulin - indications and mechanisms in cardiovascular diseases","volume":"7","author":"Nussinovitch","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.ejim.2020.04.050_bib0055","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3109\/03009740903493741","article-title":"Successful control of scleroderma myocarditis using a combination of cyclophosphamide and methylprednisolone","volume":"39","author":"Stack","year":"2010","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"10.1016\/j.ejim.2020.04.050_bib0056","first-page":"266","article-title":"Cyclophosphamide restores heart function in a patient with lupus myocarditis","volume":"7","author":"Azzam","year":"2005","journal-title":"Isr Med Assoc J"},{"issue":"5","key":"10.1016\/j.ejim.2020.04.050_bib0057","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/03009740310003956","article-title":"Intravenous cyclophosphamide improves cardiac dysfunction in lupus myocarditis","volume":"32","author":"Chan","year":"2003","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.050_bib0058","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s100670050062","article-title":"Myocarditis of mixed connective tissue disease: favourable outcome after intravenous pulsed cyclophosphamide","volume":"18","author":"Hammann","year":"1999","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.050_bib0059","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4250\/jcu.2015.23.1.40","article-title":"Cardiac involvement of churg-strauss syndrome as a reversible cause of dilated cardiomyopathy","volume":"23","author":"Jeong","year":"2015","journal-title":"J Cardiovasc Ultrasound"},{"issue":"2","key":"10.1016\/j.ejim.2020.04.050_bib0060","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.semarthrit.2017.03.023","article-title":"A cohort study reveals myocarditis to be a rare and life-threatening presentation of large vessel vasculitis","volume":"47","author":"Bechman","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.ejim.2020.04.050_bib0061","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.050_bib0062","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13104-017-2726-2","article-title":"Role of metabolites of cyclophosphamide in cardiotoxicity","volume":"10","author":"Kurauchi","year":"2017","journal-title":"BMC Res Notes"},{"issue":"14","key":"10.1016\/j.ejim.2020.04.050_bib0063","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2169\/internalmedicine.2471-18","article-title":"Successful triple combination immunosuppressive therapy with prednisolone, cyclosporine, and mycophenolate mofetil to treat recurrent giant cell myocarditis","volume":"58","author":"Akita","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.ejim.2020.04.050_bib0064","doi-asserted-by":"crossref","unstructured":"De Luca G, Cavalli G, Campochiaro C, Tresoldi M, Dagna L. Myocarditis: an interleukin-1- mediated disease?. Front. Immunol. 9:1335. 10.3389\/fimmu.2018.01335.","DOI":"10.3389\/fimmu.2018.01335"},{"issue":"3","key":"10.1016\/j.ejim.2020.04.050_bib0065","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.ijcard.2013.12.137","article-title":"Formation of the inflammasome in acute myocarditis","volume":"171","author":"Toldo","year":"2014","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2020.04.050_bib0066","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1113\/expphysiol.2012.069021","article-title":"The heart on fire: inflammasome and cardiomyopathy","volume":"98","author":"Abbate","year":"2013","journal-title":"Exp Physiol"},{"issue":"3","key":"10.1016\/j.ejim.2020.04.050_bib0067","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1084\/jem.183.3.949","article-title":"Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum","volume":"183","author":"Kumar","year":"1996","journal-title":"J Exp Med"},{"issue":"17","key":"10.1016\/j.ejim.2020.04.050_bib0068","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1161\/CIRCULATIONAHA.113.003199","article-title":"Targeting interleukin- 1 in heart disease","volume":"128","author":"Van Tassell","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ejim.2020.04.050_bib0069","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/01.RES.67.3.753","article-title":"Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiacmyocytes. Impairment of signal transduction","volume":"67","author":"Chung","year":"1990","journal-title":"Circ Res."},{"issue":"1","key":"10.1016\/j.ejim.2020.04.050_bib0070","first-page":"H141","article-title":"Suppression of beta-adrenergic responsiveness of L-type Ca2+ current by IL-1beta in rat ventricular myocytes","volume":"276","author":"Liu","year":"1999","journal-title":"Am J Physiol"},{"issue":"6 Pt 2","key":"10.1016\/j.ejim.2020.04.050_bib0071","first-page":"H2591","article-title":"Involvement of ceramide in inhibitory effect of IL-1 beta on L-type Ca2+ current in adult rat ventricular myocytes","volume":"272","author":"Schreur","year":"1997","journal-title":"Am J Physiol"},{"issue":"2 Pt 1","key":"10.1016\/j.ejim.2020.04.050_bib0072","doi-asserted-by":"crossref","first-page":"C339","DOI":"10.1152\/ajpcell.1995.268.2.C339","article-title":"G protein-mediated suppression of L-type Ca2+ current by interleukin-1 beta in cultured rat ventricular myocytes","volume":"268","author":"Liu","year":"1995","journal-title":"Am J Physiol"},{"issue":"2","key":"10.1016\/j.ejim.2020.04.050_bib0073","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00424-002-0921-y","article-title":"Chronic exposure to interleukin 1beta induces a delayed and reversible alteration in excitation-contraction coupling of cultured cardiomyocytes","volume":"445","author":"Combes","year":"2002","journal-title":"Pflugers Arch"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.050_bib0074","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/ehjcvp\/pvx018","article-title":"Interleukin-1 blockade for the treatment of pericarditis","volume":"4","author":"Buckley","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"10.1016\/j.ejim.2020.04.050_bib0075","doi-asserted-by":"crossref","first-page":"e33438","DOI":"10.1371\/journal.pone.0033438","article-title":"Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure","volume":"7","author":"Van Tassell","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejim.2020.04.050_bib0076","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)","volume":"113","author":"Van Tassell","year":"2014","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.ejim.2020.04.050_bib0077","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/clc.22719","article-title":"Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the diastolic heart failure anakinra response trial 2 (D-HART2)","volume":"40","author":"Van Tassell","year":"2017","journal-title":"Clin Cardiol"},{"issue":"6","key":"10.1016\/j.ejim.2020.04.050_bib0078","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/FJC.0000000000000378","article-title":"Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, placebo-controlled pilot study","volume":"67","author":"Van Tassell","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"issue":"20","key":"10.1016\/j.ejim.2020.04.050_bib0079","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis","volume":"117","author":"Ikonomidis","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.04.050_bib0080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fimmu.2017.00131","article-title":"Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure","volume":"8","author":"Cavalli","year":"2017","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.ejim.2020.04.050_bib0081","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1097\/CCM.0000000000001654","article-title":"Treating life-threatening myocarditis by blocking interleukin-1","volume":"44","author":"Cavalli","year":"2016","journal-title":"Crit Care Med"},{"issue":"24","key":"10.1016\/j.ejim.2020.04.050_bib0082","doi-asserted-by":"crossref","first-page":"e6656","DOI":"10.1097\/MD.0000000000006656","article-title":"Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: a case report treated with high doses (8\u200amg\/kg\/d) of anakinra","volume":"96","author":"Parisi","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejim.2020.04.050_bib0083","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3389\/fimmu.2018.01233","article-title":"Treating heart inflammation with interleukin-1 blockade in a case of erdheim\u2013chester disease","volume":"9","author":"Tomelleri","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ejim.2020.04.050_bib0084","first-page":"253","article-title":"Advances in potential targeted therapies for erdheim-chester disease","volume":"5","author":"Cavalli","year":"2017","journal-title":"Expert Opin Orphan Drugs:"},{"issue":"11","key":"10.1016\/j.ejim.2020.04.050_bib0085","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/L18-0315","article-title":"Treatment of dilated cardiomyopathy with interleukin-1 inhibition","volume":"169","author":"De Luca","year":"2018","journal-title":"Ann Intern Med"},{"issue":"20","key":"10.1016\/j.ejim.2020.04.050_bib0086","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the treatment of autoinflammatory recurrent fever syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.050_bib0087","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13075-019-1843-9","article-title":"Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease","volume":"21","author":"Cavalli","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.ejim.2020.04.050_bib0088","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ejim.2020.04.050_bib0089","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejim.2020.04.050_bib0090","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0735-1097(97)00494-4","article-title":"Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure","volume":"31","author":"Tsutamoto","year":"1998","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2020.04.050_bib0091","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1536\/jhj.45.183","article-title":"Interleukin-6 and cardiovascular diseases","volume":"45","author":"Kanda","year":"2004","journal-title":"Jpn Heart J"},{"issue":"6","key":"10.1016\/j.ejim.2020.04.050_bib0092","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00395-014-0449-2","article-title":"Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis","volume":"109","author":"Savvatis","year":"2014","journal-title":"Basic Res Cardiol"},{"issue":"7","key":"10.1016\/j.ejim.2020.04.050_bib0093","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/rheumatology\/keu019","article-title":"Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still's disease successfully treated with tocilizumab","volume":"53","author":"Savage","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ejim.2020.04.050_bib0094","doi-asserted-by":"crossref","first-page":"e35144","DOI":"10.1371\/journal.pone.0035144","article-title":"Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF \u03b2\/Smad activation and cardiac fibrosis induced by angiotensin II","volume":"7","author":"Ma","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2020.04.050_bib0095","doi-asserted-by":"crossref","first-page":"23010","DOI":"10.1038\/srep23010","article-title":"Deletion of interleukin-6 alleviated interstitial fibrosis in streptozotocin-induced diabetic cardiomyopathy of mice through affecting TGF\u03b21 and miR-29 pathways","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejim.2020.04.050_bib0096","article-title":"Tocilizumab for the treatment of myocardial inflammation shown by cardiac magnetic resonance: report of two cases and rationale for its therapeutic use","author":"Campochiaro","year":"2019","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.ejim.2020.04.050_bib0097","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/14397595.2018.1559909","article-title":"The benefits and prospects of interleukin-6 inhibitor systemic sclerosis","volume":"29","author":"Shima","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"4","key":"10.1016\/j.ejim.2020.04.050_bib0098","first-page":"321","article-title":"Serum interleukin-6 in systemic sclerosis and its correlation with disease parameters and cardiopulmonary involvement","volume":"33","author":"Abdel-Magied","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"8","key":"10.1016\/j.ejim.2020.04.050_bib0099","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/1346-8138.13827","article-title":"Critical contribution of the interleukin-6\/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis","volume":"44","author":"Taniguchi","year":"2017","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.ejim.2020.04.050_bib0100","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial(faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ejim.2020.04.050_bib0101","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/ar2965","article-title":"B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial","volume":"12","author":"Bosello","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.ejim.2020.04.050_bib0102","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/rheumatology\/kev204","article-title":"Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk","volume":"54","author":"De Luca","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ejim.2020.04.050_bib0103","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/1744666X.2018.1468251","article-title":"Tocilizumab for the treatment of giant cell arteritis","volume":"14","author":"Schirmer","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"10.1016\/j.ejim.2020.04.050_bib0104","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/CRD.0000000000000204","article-title":"Tocilizumab in giant cell arteritis","volume":"26","author":"Mariano","year":"2018","journal-title":"Cardiol Rev"},{"issue":"17","key":"10.1016\/j.ejim.2020.04.050_bib0105","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2020.04.050_bib0106","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia [published online ahead of print, 2020 Mar 30]","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2020.04.050_bib0107","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejim.2020.04.050_bib0108","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"18","key":"10.1016\/j.ejim.2020.04.050_bib0109","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejim.2020.04.050_bib0110","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejim.2020.04.050_bib0111","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.lungcan.2016.06.025","article-title":"Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung","volume":"99","author":"Semper","year":"2016","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.ejim.2020.04.050_bib0112","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","article-title":"Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab","volume":"9","author":"Tadokoro","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"Suppl 4","key":"10.1016\/j.ejim.2020.04.050_bib0113","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.ejim.2020.04.050_bib0114","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ejim.2020.04.050_bib0115","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ejim.2020.04.050_bib0116","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.050_bib0117","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.ejim.2020.04.050_bib0118","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CJI.0000000000000239","article-title":"Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin","volume":"41","author":"Jain","year":"2018","journal-title":"J Immunother"},{"issue":"7","key":"10.1016\/j.ejim.2020.04.050_bib0119","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/bjc.2017.253","article-title":"Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy","volume":"117","author":"Tay","year":"2017","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.ejim.2020.04.050_bib0120","article-title":"Progressive and reversible conduction disease with checkpoint inhibitors","volume":"33","author":"Reddy","year":"2017","journal-title":"Can J Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2020.04.050_bib0121","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11886-017-0835-0","article-title":"Cardiovascular toxicities associated with cancer immunotherapies","volume":"19","author":"Wang","year":"2017","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.050_bib0122","article-title":"Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists","volume":"34","author":"Frigeri","year":"2018","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2020.04.050_bib0123","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000498985","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature","volume":"12","author":"Agrawal","year":"2019","journal-title":"Case Rep Oncol"},{"issue":"24","key":"10.1016\/j.ejim.2020.04.050_bib0124","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ejim.2020.04.050_bib0125","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520301709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520301709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:32:15Z","timestamp":1760607135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620520301709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":125,"alternative-id":["S0953620520301709"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2020.04.050","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic strategies for virus-negative myocarditis: a comprehensive review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2020.04.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}